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OBJECTIVES This study investigated parameters of endogenous fibrinolysis, activation of coagulation and
platelets, and endothelin levels before and after elective percutaneous transluminal coronary
angioplasty (PTCA) in patients with stable coronary artery disease (CAD).
BACKGROUND Abrupt vessel closure is a serious short-term complication after PTCA and is often
unforeseeable. Detailed insight into the effect of PTCA on hemostasis, platelets and the
release of vasoconstrictive substances, which are among the mainly discussed mechanisms of
abrupt vessel closure, is needed to enhance the safety of coronary intervention.
METHODS Plasma levels of markers of platelet activity, coagulation, endogenous fibrinolysis and
endothelins were determined in 20 patients with stable CAD undergoing elective PTCA.
The blood specimens were drawn before, immediately after, 1 h after intervention and on the
next morning.
RESULTS All patients showed an initially uncomplicated PTCA. Regarding the efficacy of anticoagu-
lation after receiving 15.000 IU heparin during PTCA, two groups were compared. In eight
patients with ineffective anticoagulation production of thrombin and platelet activation
directly after and 1 h after PTCA was significantly higher compared with 12 patients with
effective anticoagulation. Despite the strong activation of coagulation, only a low fibrinolytic
response could be observed. Endothelins rose significantly after PTCA in both groups but
stayed longer on higher levels in patients with distinct thrombin generation. Three of the
eight patients without sufficient heparin treatment suffered abrupt vessel closure.
CONCLUSIONS Initially uncomplicated dilation of coronary arteries leads to systemically measurable activa-
tion of coagulation and platelets in patients with ineffective doses of heparin and release of
endothelins in all patients. Therefore, individual adjustment of anticoagulation and platelet
inhibition in combination with effective antivasospastic substances are needed in every patient
before, during and after initially uncomplicated PTCA to prevent this serious complication.
(J Am Coll Cardiol 1999;34:486–93) © 1999 by the American College of Cardiology
Although the initial success rate (90% to 95%) of percuta-
neous transluminal coronary angioplasty (PTCA) is high
(1), abrupt vessel closure remains a serious complication in
about 2% to 8% of the cases (2). Coronary thrombosis,
which occurs in up to 90% of cases within 1 h after
uncomplicated PTCA (3), is considered to be the major
cause in abrupt vessel closure (4,5). Dilation of coronary
plaques leads to more or less dissection of the artery with
exposure of subendothelial vessel wall components and
consecutive activation of the coagulation system, platelets
and release of vasoconstrictive substances (4,6,7). Some risk
factors for ischemic complications, such as unstable angina
and left ventricular function, are known, but abrupt vessel
closure is often unforeseeable. In the case of good angio-
graphic results of PTCA without flow limiting dissection or
thrombus generation, many patients receive standard doses
of heparin and aspirin only before and during intervention
without information about activation of coagulation and
platelets after PTCA.
The aim of this prospective study was the simultaneous
documentation of changes of these three mainly discussed
mechanisms of abrupt closure in patients without special
risk factors and initially uncomplicated PTCA. Hence,
parameters of coagulation (thrombin-antithrombin complex
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[TAT] antithrombin [AT] activity, prothrombin fragment
112 [F112], fibrinogen), endogenous fibrinolysis (plas-
minogen, plasminogen activator inhibitor [PAI] activity,
tissue plasminogen activator [t-PA], plasmin-a2-
antiplasmin complex [PAP], D dimer), platelet activation
(beta-thromboglobulin [beta-TG]) and vasoconstrictive
factors (endothelin-1, big endothelin-1) were determined in
20 patients with coronary artery disease (CAD) and stable
angina pectoris before and after elective and initially un-
complicated PTCA.
METHODS
Patients. For this study, 20 consecutive hospitalized male
patients with stable angina pectoris and angiographically
confirmed coronary artery disease were recruited. All pre-
sented with at least one hemodynamic relevant coronary
stenosis and underwent elective PTCA. None of the pa-
tients had a history of acute myocardial infarction, unstable
angina or coronary revascularization within the last six
months. Patients had been clinically stable for at least 2
months before entry into the study and none had suffered
severe heart failure (New York Heart Association III, IV).
Furthermore, patients with chronic or acute systemic or
inflammatory diseases, relevant organ dysfunction, neoplas-
tic disorders and other disorders of the heart were excluded.
All patients had taken low dose aspirin (100 mg/day)
regularly before admission and beta-adrenergic blocking
agents, calcium antagonists or angiotensin-converting en-
zyme inhibitors in different combination and gave their
informed consent to this investigation.
Coronary angiography and PTCA. Selective coronary
angiography was performed after the administration of
nitroglycerin and at least six standardized projections of the
left coronary artery and two projections of the right coronary
artery were obtained. Severity of CAD was classified as
single-, double- or triple-vessel disease defined by the
presence of relevant stenosis (degree .50% of the luminal
diameter) of at least one of the three major coronary artery
vessels by visual determination. Percutaneous transluminal
coronary angioplasty was performed by two experienced
investigators according to standard fashion using the Judkin
approach following right femoral artery puncture. Before
the procedure, patients received 500 mg of aspirin and
10.000 IU heparin plus an extra bolus of 5.000 IU directly
after the intervention in the catheter laboratory. The choice
of procedural variables such as size of the balloon, number
and pressure of inflations etc. was made by the operating
interventional cardiologist. To avoid vasospastic reactions
after the procedure, patients were kept on continuous
intravenous infusion of nitrates for 24 h.
Blood sampling and processing. Blood specimens were
drawn by two trained investigators in the fasting state before
PTCA (between 7:30 and 8:30 AM), immediately after
PTCA (between 12:00 and 2:00 PM), 1 h after PTCA
(between 1:00 and 3:00 PM) and on the following morning
(between 7:30 and 8:30 AM). A venipuncture of an antecu-
bital vein was performed with a 19-gauge butterfly set for
blood sampling before PTCA and on the next morning
according to a standardized protocol without tourniquet.
Before venipuncture blood sampling, patients had rested for
at least 30 min in a supine position. Immediately after as
well as 1 h after PTCA, blood was drawn from the venous
catheter sheath. The first 4 ml blood were discarded and the
samples were collected immediately in ice chilled Vacutainer
tubes (Becton Dickinson, Meylan, Cedex-France). Vacu-
tainer citrate sample tubes and EDTA anticoagulated sam-
ple tubes were used for blood collection. Plasma samples
were prepared within 30 min in a precooled centrifuge and
frozen immediately at 270°C until analysis within 3 months
after sampling.
Directly after the procedure activated partial thrombo-
plastin time (APTT) was determined in the routine labo-
ratory after the patients received 15.000 IU heparin. Normal
values in our laboratory were ,40 s. The highest measurable
APTT in our laboratory was 180 s.
Biochemic determinations. Plasma concentrations of
TAT, F112, D dimer, PAP, t-PA and beta-TG were
determined by enzyme immunoassay (Enzygnost TAT
micro, Enzygnost F112 micro, Enzygnost D dimer micro,
Enzygnost PAP [Behringwerke AG, Marburg, Germany]),
Asserachrom beta-TG (Boehringer, Mannheim, Germany),
Thrombonostika (t-PA), (Organon Teknika, Eppenheim,
Germany). Plasminogen activator inhibitor activity and
plasminogen were measured by chromogenic test
(Berichrom PAI and Plasminogen, Behringwerke AG,
Marburg, Germany), AT activity was measured by using
AT reagent and fibrinogen by Multifibren U (both Boehr-
inger, Mannheim, Germany). Endothelin-1 and big
endothelin-1 were determined by using a sensitive radioim-
munoassay (Biomedica, Wien, Austria).
Correction for hematocrit. After PTCA the hematocrit
showed significant changes (data not shown). The correc-
tion for hematocrit was carried out following Keber (8),
using the equation:
Abbreviations and Acronyms
APTT 5 activated partial thromboplastin time
AT 5 antithrombin
beta-TG 5 beta-thromboglobulin
CAD 5 coronary artery disease
F112 5 prothrombin fragment 112
PAI 5 plasminogen activator inhibitor
PAP 5 plasmin-a2-antiplasmin complex
PTCA 5 percutaneous transluminal coronary
angioplasty
TAT 5 thrombin-antithrombin complex
t-PA 5 tissue plasminogen activator
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F 5
hematocrit before PTCA 3 ~1-0.9 3 hematocrit after PTCA!
hematocrit after PTCA 3 ~1-0.9 3 hematocrit before PTCA!
Statistical analysis. Because the dependent variables of
coagulation and endogenous fibrinolysis could be influenced
by the degree of anticoagulation for statistical analysis, the
group was divided into patients with “effective” (APTT $
180 s) and “ineffective” (APTT , 70 s) anticoagulation.
The Statistical Package for Social Sciences (SPSS 6.0 for
Windows; SPSS, Munich, Germany) was used for statistical
analysis. For the comparison of two nonparametric variables,
the Mann-Whitney U test and for parametric variables the
Wilcoxon and Friedman tests were used. A significant differ-
ence between groups was assumed at a level of error of ,5%
and a significant trend at a level of error of ,10%.
RESULTS
After therapy with 15.000 IU heparin during PTCA, 12
patients (60%) reached APTT $ 180 s, 8 patients were not
effectively treated with heparin (APTT 5 34 s, 35 s,
48 s,40 s, 36 s, 62 s, 55 s, 35 s). Because of this distinct
difference of efficacy of anticoagulation, in the following
these two groups were compared. There was no statistically
significant difference between these groups for occurrence of
arterial hypertension, hypercholesterolemia, diabetes melli-
tus, smokers, ex-smokers, family history or prior myocardial
infarction. For the clinical and laboratory parameters, see
Table 1.
Coronary angiography and PTCA. Only one vessel was
dilated in every patient without use of stents, and no patient
underwent recanalization of an occluded vessel. A reduction
of the stenosis by at least 20% luminal diameter or below
50% luminal diameter could be achieved (initially successful
PTCA) in every patient. No one had suffered major peripro-
cedural complication like large, flow limiting dissection or
reocclusion of the vessel during the time of angiographic
control. See Table 2 for the angiographic characteristics and
procedural variables.
Effective anticoagulation. No significant change in F112,
TAT, AT activity, plasminogen or PAP after PTCA could
be documented. Concentrations of D dimer, endothelin-1
and big endothelin-1 rose significantly directly after angio-
plasty. Endothelins decreased in the following and turned
towards baseline levels the next morning, but D dimer
concentrations remained increased. For plasma concentra-
tions of fibrinogen, t-PA, PAI activity and beta-TG, a
contrary course was documented with a decrease 1 h after
PTCA and nearly baseline values on the next morning
except for fibrinogen, which showed a slight increase the
next day. Tables 3, 4 and 5 give detailed information about
the values determined before and after PTCA.
Ineffective anticoagulation. Plasma concentrations of
beta-TG, F112 and TAT, AT activity, D dimer, plasmin-
ogen, PAP, endothelin-1 and big endothelin-1 rose directly
after PTCA and stayed on high levels 1 h after intervention.
Plasminogen activator inhibitor activity decreased signifi-
cantly directly after PTCA and was still low 1 h after
intervention. No significant changes of concentrations after
PTCA were measured for fibrinogen and t-PA. Plasma
concentrations of F112, TAT and beta-TG were signifi-
cantly higher immediately and 1 h after intervention, and
endothelin-1 showed a strong trend to higher levels 1 h after
PTCA in patients with ineffective anticoagulation (Tables
3, 4 and 5).
Abrupt vessel closure. All 20 patients had an initially
successful dilation of the coronary artery, but 3 of the 8
ineffectively anticoagulated patients (APTT 5 62 s, 55 s,
35 s) suffered angina pectoris 2–6 h after the angioplasty
and a second coronary angiography was performed within
2 h after onset of symptoms. Abrupt vessel closure was
Table 1. Clinical Characteristics and Laboratory Parameters (Mean 6 SD) of the Study
Population—Comparison Between Patients With Effective and Ineffective Anticoagulation (AC)
Effective AC
(n 5 12)
Ineffective AC
(n 5 8) p
Age (median [min/max]) 66 (49–72) years 59 (54–73) years n.s.
Body weight (kg) 81.3 6 9.4 85.0 6 9.2 n.s.
Laboratory parameters
Cholesterol (mg/dl) 231 6 50 205 6 47 n.s.
LDL cholesterol (mg/dl) 176 6 55 149 6 34 n.s.
HDL cholesterol (mg/dl) 38 6 9 44 6 15 n.s.
Triglycerides (mg/dl) 205 6 114 170 6 36 n.s.
Glucose (mg/dl) 115 6 37 87 6 47 n.s.
Uric acid (mg/dl) 5.2 6 1.2 5.6 6 1.5 n.s.
Fibrinogen (mg/dl) 307 6 97 327 6 91 n.s.
Platelets (3103) 205 6 26 250 6 84 n.s.
Leucocytes (3103) 6.3 6 1.0 6.9 6 1.5 n.s.
C-reactive protein (mg/dl) 0.5 6 0.4 0.5 6 0.4 n.s.
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documented in all three cases. The patients were success-
fully redilated and 250.000 IU of urokinase was given for
intracoronary lysis. Despite successful redilation, the three
patients developed an increase in creatinkinase (CK 5 142
U/l, 180 U/l, 220 U/l).
There was a distinct difference before PTCA between
patients with and without complication in the subgroup of
ineffectively anticoagulated patients in plasma concentra-
tions of t-PA ([median; range] without abrupt vessel clo-
sure: 17.22 [12.74 to 20.0] mg/l; with abrupt vessel closure:
11.41 [11.06 to 14.39] mg/l) and PAI activity (without
abrupt vessel closure: 5.15 [2.0 to 9.09] U/ml; with abrupt
vessel closure: 8.66 [7.81 to 11.93] U/ml). For patients with
complications, the highest big endothelin-1 concentrations
1 h after PTCA could be documented compared with
ineffectively anticoagulated patients without acute vessel
closure ([range] without abrupt vessel closure: 2.46 to
4.92 fmol/ml; with abrupt vessel closure: 5.71– 6.38
fmol/ml).
DISCUSSION
It is well known that dilation of coronary arteries in most
cases is accompanied by a dissection of the vessel (2,9,10,11)
Table 2. Characteristics of the Angiography and Angioplasty Procedure of the Study Population
(Mean 6 SD)
Effective AC
(n 5 12)
Ineffective AC
(n 5 8) p
Severity of CAD n.s.
single-vessel disease 3 3
double-vessel disease 3 4
triple-vessel disease 6 1
Small angiographically visible
dissection of the dilated vessel
4 3* n.s.
Balloon size (mm) 2.6 6 0.2 2.6 6 0.3 n.s.
Balloon pressure (atm) 9 6 2 9 6 2 n.s.
Time of balloon inflation(s) 213 6 79 366 6 238 n.s.
No. of balloon inflations 4 6 1 5 6 3 n.s.
Duration of whole procedure (min) 38 6 14 44 6 20 n.s.
Contrast medium (ml) 73 6 22 95 6 61 n.s.
*Only one of these three patients belonged to the group with acute coronary artery closure.
Table 3. Parameters of Activation of Coagulation and Platelets in Course After PTCA—Comparison Between Patients With
Effective (n 5 12) and Ineffective (n 5 8) Anticoagulation (AC) (Median [Range])
Before Directly after 1 h after Next morning* Friedman-test†
Fibrinogen (mg/dl)
effective AC 284 (208–574) 276 (226–646) 281 (234–640) 326 (263–636) p , 0.05
ineffective AC 309 (232–459) 301 (219–415) 321 (252–410) 385 (288–458) n.s.
u-test n.s. n.s. n.s. ø
F112 (nmol/ml)
effective AC 0.94 (0.21–5.38) 0.78 (0.30–1.39) 0.81 (0.23–1.35) 1.06 (0.30–1.81) n.s.
ineffective AC 0.89 (0.72–1.34) 2.16 (1.33–3.25) 2.29 (1.44–4.27) 0.90 (0.63–1.87) p , 0.01
u-test n.s. p 5 0.0004 p 5 0.0002 ø
TAT (mg/l)
effective AC 2.5 (2.0–60) 3.0 (1.9–7.0) 2.8 (2.1–9.3) 4.7 (2.1–25.5) n.s.
ineffective AC 2.7 (2.0–56.1) 18.2 (14.8–58.7) 23.8 (11.2–49.1) 3.6 (3.3–12.9) p , 0.05
u-test n.s. p 5 0.0002 p 5 0.0002 ø
AT activity (%)
effective AC 102 (58–112) 104 (61–127) 103 (61–132) 107 (60–135) n.s.
ineffective AC 103 (73–121) 112 (76–127) 117 (77–130) 118 (82–135) p , 0.001
u-test n.s. n.s. n.s. ø
Beta-TG (IU/ml)
effective AC 40 (15–195) 25 (13–36) 25 (12–34) 33 (11–182) p , 0.05
ineffective AC 24 (12–46) 43 (33–192) 39 (35–174) 31 (18–61) p , 0.01
u-test n.s. p 5 0.0004 p 5 0.0002 ø
*At this time the group with ineffective anticoagulation consisted only of the five patients without acute closure; †Friedman-test compared only the time points before, directly
after and 1 h after PTCA.
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and consecutive activation of coagulation, platelets and
release of vasoconstrictive substances. Therefore, every pa-
tient receives heparin, aspirin and nitrates before and during
PTCA to reduce the activation of platelets and systemic
coagulation and to minimize vasospastic reactions. Because
measurement of activated clotting time as a bedside test was
not available in our clinic at the time of the study, effec-
tiveness of anticoagulation was determined by APTT in our
routine laboratory with temporary delay.
Coagulation system and platelets. Eight of the 20 pa-
tients (40%) showed an ineffective anticoagulation directly
after PTCA with substantial thrombin generation, indi-
cated by significantly increasing plasma concentrations of
F112 and TAT. In patients with effective anticoagulation,
there was no significant change of these parameters during
the intervention. Despite an individual response to heparin,
for example, by differences in plasma concentrations of
heparin-neutralizing proteins or body weight, most patients
would show “highly effective” (.180 s) APTT values after
receiving the empirical dose of 15.000 IU heparin as
intravenous bolus. Hence, ineffective anticoagulation with
standard doses of heparin after intervention resulted prob-
ably not only from an individual response to heparin, but
from a much stronger activation of coagulation during
PTCA. Different thrombogenicity of coronary plaques and
its dependence on the plaque-components were described
before (12,13) and could explain the different level of
thrombin generation. In contrast with Marmur et al. (14),
who documented thrombin generation in a substantial
portion of patients shortly after PTCA locally in the
Table 4. Parameters of Endogenous Fibrinolysis in Course After PTCA—Comparison Between Patients With Effective (n 5 12) and
Ineffective (n 5 8) Anticoagulation (AC) (Median [Range])
Before Directly After 1 h After Next Morning* Friedman-Test†
Plasminogen (U/ml)
effective AC 107 (85–120) 106 (80–131) 110 (80–133) 111 (90–140) n.s.
ineffective AC 120 (105–132) 120 (103–137) 124 (111–142) 142 (122–154) p , 0.01
u-test p 5 0.0150 p 5 0.0253 p 5 0.0168 ø
PAI activity (U/ml)
effective AC 4.4 (1.5–14.2) 3.2 (0.2–4.9) 3.2 (1.4–5.6) 5.1 (2.6–20.4) p , 0.01
ineffective AC 7.1 (2.0–11.9) 2.7 (0.3–4.1) 4.4 (1.0–5.8) 5.4 (1.7–14.6) p , 0.05
u-test n.s. n.s. n.s. ø
t-PA (mg/l)
effective AC 12.8 (6.5–20.0) 10.8 (4.4–20.8) 10.4 (3.3–21.2) 13.6 (6.6–21.2) p , 0.05
ineffective AC 15.5 (11.1–20.0) 13.9 (8.7–23.9) 13.2 (8.9–24.6) 19.1 (12.5–26.5) n.s.
u-test n.s. n.s. n.s. ø
PAP (mg/l)
effective AC 275 (161–1130) 329 (182–893) 331 (220–854) 266 (133–671) n.s.
ineffective AC 380 (185–462) 508 (210–5552) 479 (386–5846) 514 (271–583) p , 0.01
u-test n.s. n.s. n.s. ø
D dimer (mg/l)
effective AC 25 (10–351) 44 (10–495) 47 (11–635) 46 (10–699) p , 0.001
ineffective AC 27 (15–50) 48 (15–218) 66 (20–384) 97 (29–181) p , 0.01
u-test n.s. n.s. n.s. ø
*At this time the group with ineffective anticoagulation consisted only of the five patients without acute closure; †Friedman-test compared only the time points before, directly
after and 1 h after PTCA.
Table 5. Endothelin-1 (ET-1) and Big endothelin-1 (BET-1) in Course After PTCA—Comparison Between Patients With Effective
(n 5 12) and Ineffective (n 5 8) Anticoagulation (AC) (Median [Range])
Before Directly After 1 h After Next Morning* Friedman-Test†
ET-1 (fmol/ml)
effective AC 0.65 (0.27–0.96) 1.61 (0.83–2.34) 1.12 (0.71–2.11) 1.00 (0.23–1.75) p , 0.001
ineffective AC 0.76 (0.54–1.11) 1.56 (0.48–1.77) 1.67 (1.14–2.52) 1.10 (0.59–1.60) p , 0.01
u-test n.s. n.s. p 5 0.0538 ø
BET-1 (fmol/ml)
effective AC 1.82 (0.73–2.81) 4.75 (2.32–6.87) 3.62 (2.50–6.20) 2.57 (0.64–5.12) p , 0.001
ineffective AC 1.64 (1.05–2.86) 4.40 (2.82–5.10) 4.46 (2.46–6.38) 1.98 (1.49–4.78) p , 0.01
u-test n.s. n.s. n.s. ø
*At this time, the group with ineffective anticoagulation consisted only of the five patients without acute closure; †Friedman-test compared only the time points before, directly
after and 1 h after PTCA.
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coronary artery despite an activated clotting time over 300 s,
in our study, activation of coagulation could be measured
systemically but only in the ineffectively treated subgroup.
Immediately after PTCA and therapy with 500 mg aspirin,
plasma concentrations of beta-TG decreased in patients
with effective APTT values, indicating either effective plate-
let inhibition or no substantial platelet activation. In con-
trast with this, in patients with distinct thrombin generation
beta-TG increased after PTCA with statistical significant
difference between both groups. The usefulness of antiplate-
let drugs in preventing acute ischemic complications after
angioplasty was previous described (15,16). This platelet
activation could be due to the high plasma concentration of
thrombin, a potent stimulus of platelet activation, and to
balloon-mediated injury of the plaque with consecutive
contact of the blood with von Willebrand factor, collagen
and other platelet activators. A strong platelet activation
could lead to reduced heparin effect by release of platelet
factor 4, a heparin-neutralizing protein (17). The parallel
activation of coagulation and platelets only in a subgroup
with low level anticoagulation and missing substantial
thrombin generation before PTCA in both groups supports
the hypothesis of a high thrombogenic plaque in these
patients. The lack of visible angiographic complications like
a distinct dissection or thrombus formation directly after
PTCA showed the uncertainty of the visible result to indicate
changes of hemostasis. Recently published data of Narins (18)
and Kunert (19) showed a strong relationship between low
anticoagulation determined by the activated clotting time and
the risk of abrupt vessel closure after PTCA. In our study,
three patients developed an early reocclusion of the vessel. This
unexpected complication rate of 15% was quite high in our
rather small collective and does not reflect the overall rate of
our institution (20). Out of a random coincidence there was no
other obvious cause; nevertheless, it was remarkable that all
three patients belonged to the group with ineffective heparin
therapy respective with strong activation of coagulation and
platelets. This supports the findings of Narins (18) and Kunert
(19). Ineffective heparin treatment in our study was not caused
by low AT activity or different body weight because of normal
AT activity and similar body weight in both groups. There was
also no difference in fibrinogen plasma levels, one discussed risk
factor in cardiovascular disease (21,22,23).
Endogenous fibrinolysis. The lower levels of t-PA con-
centrations and PAI activity immediately and 1 h after
PTCA in both groups were probably based on circadian
variation of these parameters (24). The blood of the first and
last measurement was taken early in the morning and the
blood after PTCA in the late morning or at noon. The assay
system for measuring t-PA concentrations determines com-
plexes of t-PA and PAI. This explains the simultaneous
decrease in both parameters after PTCA. Concentrations of
PAP showed a significant increase after PTCA in patients
with high thrombin generation, and a similar rise of D
dimer concentrations in both groups. Despite the strong
activation of coagulation, the concentrations of PAP and D
dimer showed no difference between the patients with and
without thrombin generation. The absence of a strong rise
in D dimer and PAP concentrations in the patients with
distinct activation of the coagulation system may show their
insufficiency to enhance their endogenous fibrinolysis. This
lack of effective activation of fibrinolysis despite the signif-
icant higher plasminogen levels in this group suggests a
disturbance in fibrinolytic response as a cause of a low
fibrinolytic potency. These findings also show the impor-
tance of the determination and prevention of thrombin
generation after PTCA.
Interestingly the three patients with acute vessel closure
had higher plasma activity of PAI and distinct lower plasma
levels of t-PA before intervention in comparison with the
patients without complication in the subgroup of ineffec-
tively treated patients. High PAI activity levels are reported
in coronary artery disease and acute myocardial infarction
(25,26).
Endothelins. The strong vasoconstrictor endothelin-1 and
its precursor big endothelin-1 are discussed with regard to
their role in coronary artery disease and acute ischemic
syndromes (27,28,29,30,31). Vasoconstriction may be also
an important factor in abrupt vessel closure (7).
The significant increase of both peptides directly after
PTCA in both groups may indicate endothelial damage.
Shear stress and endothelial injury stimulates endothelin-1
production (27,32,33). Also myocardial ischemia during
balloon inflation and stress reaction with release of cat-
echolamines could contribute to endothelin-1 release in
both groups (27,33). One hour after intervention, the
plasma concentrations of endothelin-1 and big endothelin-1
in the patients with effective anticoagulation decreased
while endothelin-1 and big endothelin-1 concentrations
remained at higher levels in patients with activated coagu-
lation systems. The cause of the elevated levels of the
vasoconstrictors in ineffective anticoagulated patients can be
a combination of the increased generation of thrombin, a
potent stimulus of endothelin-1 production (34), or angio-
graphically nonvisible extensive vessel injury. Endothelin-1
and big endothelin-1 levels 1 h after PTCA in patients with
abrupt closure belonged to the highest values in the sub-
group compared with patients without complication. Be-
cause of its longer half time and higher circulating plasma
levels, big endothelin-1 may be the more conclusive param-
eter. A higher sensitivity of big endothelin-1 for discrimi-
nation of patients with stable, unstable angina pectoris and
acute myocardial infarction was documented previously
(31). Independent of the mechanisms of endothelin-1
release, elevated levels of the peptide measured in peripheral
veins are probably much higher at the place of interest and
could contribute to abrupt vessel closure.
There was no difference in endothelin-1 and big
endothelin-1 concentrations between the groups with
and without early complications before PTCA and di-
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rectly after the procedure. But a missing decrease or
further increase of plasma concentrations in course after
intervention may be an indicator of higher risks for compli-
cations. Big endothelin-1 as a predictor of a severe course of
ischemia in patients with unstable angina and endothelin-1 as
a prognostic factor after acute myocardial infarction was shown
recently (31,35).
Study limitations. Interpretation of this study is limited
by the small sample size and the accidental high rate of
abrupt coronary artery closures. For measurement of
effectiveness of anticoagulation with high doses of hep-
arin during PTCA, the determination of activated clot-
ting time would have been more reliable. Kunert et al.
(19) reported 150 patients with an APTT .180 s after
PTCA and after injection of 20.000 IU heparin but who
had a range of activated clotting time between 167 s and
628 s. This means that “highly effective” APTT could be
“ineffective,” because activated clotting times .300 s
during PTCA are currently recommended today to pre-
vent abrupt vessel closure. Even though our data indicate
a therapeutic effect on thrombin generation, even more
intense anticoagulation guided by activated clotting time
measurements may be necessary to suppress elevated
concentrations of thrombin in the local environment of
the dilated vessel. Therefore, this device should be
routinely used during PTCA if possible.
Conclusions and clinical implications. The elevation of
the parameters indicating activation of coagulation system
or platelets directly after PTCA agreed with an ineffective
anticoagulation or vice versa and clearly showed a strong
association with the development of early vessel occlusion
after an initially uncomplicated procedure. This supports
the findings of other authors about the meaning of effective
anticoagulation to avoid abrupt vessel closure after PTCA
(18,19). Risk factors for development of abrupt vessel
closure in our study seem to be based on a combination of
vasoconstriction, activation of the coagulation system and
platelets as well as a low fibrinolytic potency. These findings
and their agreement with the results of other authors should
lead to further studies which investigate the benefit of a
prolonged and intensified therapy with heparin or with
more specific thrombin inhibitors or platelet inhibitors in
this subgroup of patients after initially uncomplicated
PTCA. Effective anticoagulation should be determined by
activated clotting time, which could be shown to be superior
to measurement of APTT. Detailed insights into the
mechanism of abrupt closure, especially individual measure-
ment of effective anticoagulation and platelet inhibition as
well as development of respective experience with new
therapeutic options such as endothelin-1- or endothelin-1
receptor-antagonists, and new platelet inhibitors such as
glycoprotein IIb/IIIa receptor antibodies will probably help
to prevent this serious complication.
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